Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at…
Boehringer Ingelheim today announced the LUME-Colon 1 trial, investigating nintedanib plus best supportive care versus BSC alone, met one of the co-primary endpoints of progression-free survival in pre-treated patients with metastatic colorectal cancer…